Genetics and Pathogenesis of Diffuse Large B-Cell LymphomaRoland Schmitz, Louis M. Staudt, George W. Wright et al.|New England Journal of Medicine|2018Cited by 2.3k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Alessandra Tedeschi et al.|New England Journal of Medicine|2015Cited by 1.6k
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Sarit Assouline et al.|The Lancet Oncology|2022Cited by 429
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D. Jacobsen, Nancy L. Bartlett|Blood|2015Cited by 300
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell LymphomasMaximillian Rosario, Todd A. Fehniger, Bai Liu et al.|Clinical Cancer Research|2015Cited by 147